Page 1715 - Williams Hematology ( PDFDrive )

1690 Part XI: Malignant Lymphoid Diseases Chapter 103: Cutaneous T-Cell Lymphoma (Mycosis Fungoides and Sézary Syndrome) 1691

54. Epstein EH Jr, Levin DL, Croft JD Jr, et al: Mycosis fungoides. Survival, prognos- 84. Lessin SR, Duvic M, Guitart J, et al: Topical chemotherapy in cutaneous T-cell lym-
tic features, response to therapy, and autopsy findings. Medicine (Baltimore) 51: phoma: Positive results of a randomized, controlled, multicenter trial testing the effi-
61–72, 1972. cacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA
55. Zackheim HS, Amin S, Kashani-Sabet M, et al: Prognosis in cutaneous T-cell lym- Dermatol 149:25–32, 2013.
phoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol 40: 85. Vonderheid EC, Van Scott EJ, Johnson WC, et al: Topical chemotherapy and immuno-
418–425, 1999. therapy of mycosis fungoides: Intermediate-term results. Arch Dermatol 113:454–462,
56. Scarisbrick JJ, Whittaker S, Evans AV, et al: Prognostic significance of tumor burden in 1977.
the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 86. Du Vivier A, Vonderheid EC, Van Scott EJ, et al: Mycosis fungoides, nitrogen mustard
97:624–630, 2001. and skin cancer. Br J Dermatol 99:61–63, 1978.
57. Muche JM, Lukowsky A, Asadullah K, et al: Demonstration of frequent occurrence of 87. Zackheim HS, Epstein EH Jr, Grekin DA: Treatment of mycosis fungoides with topical
clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lym- BCNU. Cancer Treat Rep 63:623, 1979.
phoma. Blood 90:1636–1642, 1997. 88. Pileri A, Delfino C, Grandi V, et al: Role of bexarotene in the treatment of cutaneous
58. Vonderheid EC, Pena J, Nowell P: Sézary cell counts in erythrodermic cutaneous T-cell T-cell lymphoma: The clinical and immunological sides. Immunotherapy 5:427–433,
lymphoma: Implications for prognosis and staging. Leuk Lymphoma 47:1841–1856, 2013.
2006. 89. Kempf W, Kettelhack N, Duvic M, et al: Topical and systemic retinoid therapy for cuta-
59. Vonderheid EC, Bernengo MG, Burg G, et al: Update on erythrodermic cutaneous neous T-cell lymphoma. Hematol Oncol Clin North Am 17:1405–1419, 2003.
T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am 90. Martin AG: Bexarotene gel: A new skin-directed treatment option for cutaneous T-cell
Acad Dermatol 46:95–106, 2002. lymphomas. J Drugs Dermatol 2:155–167, 2003.
60. Bergman R: How useful are T-cell receptor gene rearrangement studies as an adjunct to 91. Morison WL: In vivo effects of psoralens plus longwave ultraviolet radiation on immu-
the histopathologic diagnosis of mycosis fungoides? Am J Dermatopathol 21:498–502, nity. Natl Cancer Inst Monogr 66:243–246, 1984.
1999. 92. Baron ED, Stevens SR: Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther
61. Cherny S, Mraz S, Su L, et al: Heteroduplex analysis of T-cell receptor gamma gene rear- 16:303–310, 2003.
rangement as an adjuvant diagnostic tool in skin biopsies for erythroderma. J Cutan 93. Ramsay DL, Lish KM, Yalowitz CB, et al: Ultraviolet-B phototherapy for early-stage
Pathol 28:351–355, 2001. cutaneous T-cell lymphoma. Arch Dermatol 128:931–933, 1992.
62. Delfau-Larue MH, Dalac S, Lepage E, et al: Prognostic significance of a polymerase 94. Samson Yashar S, Gielczyk R, Scherschun L, et al: Narrow-band ultraviolet B treatment
chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of for vitiligo, pruritus, and inflammatory dermatoses. Photodermatol Photoimmunol
patients with mycosis fungoides. Blood 92:3376–3380, 1998. Photomed 19:164–168, 2003.
63. Poszepczynska-Guigne E, Bagot M, Wechsler J, et al: Minimal residual disease in myco- 95. Deaver D, Cauthen A, Cohen G, et al: Excimer laser in the treatment of mycosis fun-
sis fungoides follow-up can be assessed by polymerase chain reaction. Br J Dermatol goides. J Am Acad Dermatol 70:1058–1060, 2014.
148:265–271, 2003. 96. Drucker AM, Baibergenova A, Rosen CF, et al: Narrowband UVB as an effective substi-
64. Wood GS, Tung RM, Haeffner AC, et al: Detection of clonal T-cell receptor gamma tute for psoralen plus UVA: Lessons from a psoralen shortage. Photodermatol Photoim-
gene rearrangements in early mycosis fungoides/Sézary syndrome by polymerase chain munol Photomed 28:267–268, 2012.
reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 97. Gilchrest BA: Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treat
103:34–41, 1994. Rep 63:663–667, 1979.
65. Long JC, Mihm MC: Mycosis fungoides with extracutaneous dissemination: A distinct 98. Herrmann JJ, Roenigk HH Jr, Hurria A, et al: Treatment of mycosis fungoides with
clinicopathologic entity. Cancer 34:1745–1755, 1974. photochemotherapy (PUVA): Long-term follow-up. J Am Acad Dermatol 33:234–242,
66. Smith DI, Vnencak-Jones CL, Boyd AS: T-lymphocyte clonality in benign lichenoid 1995.
keratoses. J Cutan Pathol 29:623–624, 2002. 99. Roenigk HH Jr, Kuzel TM, Skoutelis AP, et al: Photochemotherapy alone or combined
67. Nihal M, Mikkola D, Horvath N, et al: Cutaneous lymphoid hyperplasia: A lymphopro- with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest
liferative continuum with lymphomatous potential. Hum Pathol 34:617–622, 2003. Dermatol 95:198S–205S, 1990.
68. Holm N, Flaig MJ, Yazdi AS, et al: The value of molecular analysis by PCR in the diag- 100. Geskin L: ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin
nosis of cutaneous lymphocytic infiltrates. J Cutan Pathol 29:447–452, 2002. Therapy Lett 12:1–4, 2007.
69. Shieh S, Mikkola DL, Wood GS: Differentiation and clonality of lesional lymphocytes in 101. Orenstein A, Haik J, Tamir J, et al: Photodynamic therapy of cutaneous lymphoma
pityriasis lichenoides chronica. Arch Dermatol 137:305–308, 2001. using 5-aminolevulinic acid topical application. Dermatol Surg 26:765–769; discussion
70. Zucker-Franklin D: The role of human T cell lymphotropic virus type I tax in the devel- 769–770, 2000.
opment of cutaneous T cell lymphoma. Ann N Y Acad Sci 941:86–96, 2001. 102. Edstrom DW, Porwit A, Ros AM: Photodynamic therapy with topical 5-aminolevulinic
71. Kikuchi A, Ohata Y, Matsumoto H, et al: Anti-HTLV-1 antibody positive cutaneous acid for mycosis fungoides: Clinical and histological response. Acta Derm Venereol
T-cell lymphoma. Cancer 79:269–274, 1997. 81:184–188, 2001.
72. Palmer RA, Keefe M, Slater D, et al: Case 4: Pagetoid reticulosis (Woringer-Kolopp 103. Jones GW, Kacinski BM, Wilson LD, et al: Total skin electron radiation in the man-
type) or unilesional mycosis fungoides (MF). Clin Exp Dermatol 27:345–346, 2002. agement of mycosis fungoides: Consensus of the European Organization for Research
73. Wood GS, Weiss LM, Hu CH, et al: T-cell antigen deficiencies and clonal rearrange- and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad
ments of T-cell receptor genes in pagetoid reticulosis (Woringer-Kolopp disease). Dermatol 47:364–370, 2002.
N Engl J Med 318:164–167, 1988. 104. Hoppe R: Total skin electron beam therapy in the management of mycosis fungoides, in
74. Cohen EL: Woringer-Kolopp disease (pagetoid reticulosis). Clin Exp Dermatol 3: The Role of High Energy Electrons in the Treatment of Cancer, edited by Vaeth M, p 80.
447–450, 1978. S Karger, Basel, Switzerland, 1991.
75. Scarabello A, Fantini F, Giannetti A, et al: Localized pagetoid reticulosis (Woringer-Kolopp 105. Kazmierska J: Clinical results of the total skin electron irradiation of the mycosis fun-
disease). Br J Dermatol 147:806, 2002. goides in adults. Conventional fractionation and low dose schemes. Rep Pract Oncol
76. Nakada T, Sueki H, Iijima M: Disseminated pagetoid reticulosis (Ketron-Goodman disease): Radiother 19:99–103, 2014.
Six-year follow-up. J Am Acad Dermatol 47:S183–S186, 2002. 106. Akilov OE, Grant C, Frye R, et al: Low-dose electron beam radiation and romidep-
77. Fierro MT, Novelli M, Savoia P, et al: CD45RA+ immunophenotype in mycosis fun- sin therapy for symptomatic cutaneous T-cell lymphoma lesions. Br J Dermatol 167:
goides: Clinical, histological and immunophenotypical features in 22 patients. J Cutan 194–197, 2012.
Pathol 28:356–362, 2001. 107. Harrison C, Young J, Navi D, et al: Revisiting low-dose total skin electron beam therapy
78. Haghighi B, Smoller BR, LeBoit PE, et al: Pagetoid reticulosis (Woringer-Kolopp dis- in mycosis fungoides. Int J Radiat Oncol Biol Phys 81:e651–7, 2011.
ease): An immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 108. Kamstrup MR, Specht L, Skovgaard GL, et al: A prospective, open-label study of low-
13:502–510, 2000. dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys
79. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al: Primary and secondary cuta- 71:1204–1207, 2008.
neous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous 109. Do JH, McLaughlin SS, Gaspari AA: Topical imiquimod therapy for cutaneous T-cell
Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for lymphoma. Skinmed 2:316–318, 2003.
diagnosis and treatment. Blood 95:3653–3661, 2000. 110. Dummer R, Urosevic M, Kempf W, et al: Imiquimod induces complete clearance of a
80. Bekkenk MW, Vermeer MH, Jansen PM, et al: Peripheral T-cell lymphomas unspecified PUVA-resistant plaque in mycosis fungoides. Dermatology 207:116–118, 2003.
presenting in the skin: Analysis of prognostic factors in a group of 82 patients. Blood 111. Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment of
102:2213–2219, 2003. refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial
81. Willemze R, Meijer CJ: Primary cutaneous CD30-positive lymphoproliferative disor- results. J Clin Oncol 19:2456–2471, 2001.
ders. Hematol Oncol Clin North Am 17:1319–1332, vii–viii, 2003. 112. Duvic M, Martin AG, Kim Y, et al: Phase 2 and 3 clinical trial of oral bexarotene (Targretin
82. Reitamo S, Rissanen J, Remitz A, et al: Tacrolimus ointment does not affect collagen capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lym-
synthesis: Results of a single-center randomized trial. J Invest Dermatol 111:396–398, phoma. Arch Dermatol 137:581–593, 2001.
1998. 113. Assaf C, Bagot M, Dummer R, et al: Minimizing adverse side-effects of oral bexarotene
83. Pomerantz RG, Campbell LS, Jukic DM, et al: Posttransplant cutaneous T-cell lym- in cutaneous T-cell lymphoma: An expert opinion. Br J Dermatol 155:261–266, 2006.
phoma: Case reports and review of the association of calcineurin inhibitor use with 114. Zhang C, Duvic M: Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol
posttransplant lymphoproliferative disease risk. Arch Dermatol 146:513–516, 2010. Ther 19:264–271, 2006.

Kaushansky_chapter 103_p1679-1692.indd 1690 9/21/15 12:51 PM